Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Axsome Therapeutics (NASDAQ:AXSM) had its price objective increased by equities research analysts at Needham & Company LLC from $267.00 to $268.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price would suggest a potential upside of 21.33% from the company’s current price.

A number of other equities analysts also recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $272.00 price objective on shares of Axsome Therapeutics in a research report on Monday, May 4th. Piper Sandler restated an “overweight” rating and issued a $258.00 target price on shares of Axsome Therapeutics in a report on Monday, May 4th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 target price on shares of Axsome Therapeutics in a research note on Thursday, June 11th. HC Wainwright reiterated a “buy” rating and set a $290.00 price target on shares of Axsome Therapeutics in a report on Wednesday, July 15th. Finally, Wells Fargo & Company boosted their price target on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company an “overweight” rating in a research report on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $266.20.

Axsome Therapeutics Stock Up 3.8%

Shares of NASDAQ AXSM opened at $220.89 on Tuesday. The stock has a market cap of $11.37 billion, a PE ratio of -59.22 and a beta of 0.65. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. Axsome Therapeutics has a 12-month low of $102.67 and a 12-month high of $260.19. The company has a 50-day moving average of $236.76 and a 200 day moving average of $204.41.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). The business had revenue of $218.38 million during the quarter, compared to analysts’ expectations of $221.11 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%. As a group, sell-side analysts predict that Axsome Therapeutics will post -2.48 EPS for the current fiscal year.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 4,660 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $213.95, for a total value of $997,007.00. Following the transaction, the chief executive officer owned 7,229 shares of the company’s stock, valued at $1,546,644.55. This represents a 39.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Mark Coleman sold 643 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $249.00, for a total transaction of $160,107.00. Following the transaction, the director directly owned 30,389 shares of the company’s stock, valued at approximately $7,566,861. This trade represents a 2.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 200,766 shares of company stock worth $46,685,646 in the last 90 days. Insiders own 20.60% of the company’s stock.

Institutional Trading of Axsome Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its stake in Axsome Therapeutics by 14.9% during the second quarter. GAMMA Investing LLC now owns 347 shares of the company’s stock worth $85,000 after purchasing an additional 45 shares in the last quarter. Birchview Capital LP raised its holdings in shares of Axsome Therapeutics by 1.0% in the 4th quarter. Birchview Capital LP now owns 6,061 shares of the company’s stock valued at $1,107,000 after buying an additional 61 shares during the period. PNC Financial Services Group Inc. lifted its stake in Axsome Therapeutics by 3.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,921 shares of the company’s stock worth $351,000 after acquiring an additional 65 shares in the last quarter. Xponance LLC lifted its stake in Axsome Therapeutics by 2.4% during the 4th quarter. Xponance LLC now owns 3,265 shares of the company’s stock worth $596,000 after acquiring an additional 76 shares in the last quarter. Finally, Assetmark Inc. grew its position in Axsome Therapeutics by 7.2% in the 1st quarter. Assetmark Inc. now owns 1,182 shares of the company’s stock valued at $200,000 after acquiring an additional 79 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Management indicated a potentially significant development cadence, targeting approximately one new drug application (NDA) annually through 2030. AXS-12, its narcolepsy candidate, is scheduled for a May 1, 2027 PDUFA date, providing a defined regulatory catalyst. Axsome signals 1 NDA per year through 2030 as AXS-12 targets May 1, 2027 PDUFA
• Positive Sentiment: Axsome’s commercial sales growth helped offset the quarterly earnings shortfall, supporting investor confidence in the company’s marketed-product base and revenue trajectory. Axsome Therapeutics shares gain 2% as strong sales growth offsets Q2 miss
• Positive Sentiment: The company’s second-quarter business update and presentation emphasized ongoing pipeline progress and corporate development, reinforcing the longer-term growth case for AXSM. Axsome Therapeutics Announces Q2 2026 Financial Results and Updates Corporate Presentation
• Neutral Sentiment: Second-quarter revenue was $218.38 million, close to—but below—the $221.11 million analyst consensus. Coverage is focused on whether key operating metrics and sales trends can sustain Axsome’s mid-cap growth profile. Axsome Q2 Earnings: What Key Metrics Have to Say
• Negative Sentiment: Axsome reported a second-quarter loss of $0.99 per share, wider than the $0.89 consensus estimate. The company remains unprofitable, with a negative net margin, so execution and progress toward sustainable earnings remain important risks. Axsome Therapeutics Second-Quarter Earnings Results

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.